BCL9
BCL9 (B-cell CLL/lymphoma 9) is a nuclear transcription coactivator that takes part in Wnt pathway signal transduction and promotes the transcriptional activity of beta-catenin. It is a member of the BCL9 family and belongs to the Wnt enhanceosome complex gene group. Browse Assay Genie's current range of BCL9 research reagents below, or read on for the biology behind the target.
BCL9 is involved in signal transduction through the Wnt pathway. According to UniProt, it promotes the transcriptional activity of beta-catenin, which places the BCL9 protein among the coactivators that support Wnt-dependent gene expression in the nucleus. The protein is localised to the nucleus, consistent with its role in transcriptional regulation.
The human BCL9 gene encodes B-cell CLL/lymphoma 9 protein and is classed by HGNC in the Wnt enhanceosome complex gene group. The protein belongs to the BCL9 family. The mouse ortholog is Bcl9, which is relevant when planning work in murine models. Researchers studying Wnt signalling often use a BCL9 antibody or a BCL9 ELISA kit to examine its abundance and behaviour alongside beta-catenin.
BCL9 was named after its association with B-cell malignancies. NCBI Gene reports that it is associated with B-cell acute lymphoblastic leukaemia and may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Overexpression of BCL9 may be of pathogenic significance in these diseases. The previous names recorded by HGNC are B cell CLL/lymphoma 9 and BCL9, transcription coactivator. Note that the BCL9 name does not imply close relationship to other BCL-named genes such as Bcl-2; the designation reflects the way the gene was first identified.
BCL9 is involved in Wnt pathway signal transduction, making it a relevant target for studying how pathway output is regulated.
BCL9 promotes the transcriptional activity of beta-catenin, so it is studied in work on beta-catenin-dependent gene expression.
BCL9 is associated with B-cell acute lymphoblastic leukaemia, and its overexpression may be of pathogenic significance in B-cell malignancies.
BCL9 may be a translocation target in B-cell malignancies with 1q21 abnormalities, which makes it a focus in cytogenetic studies.
BCL9 is involved in signal transduction through the Wnt pathway. UniProt annotates it as promoting the transcriptional activity of beta-catenin. It is a nuclear protein and a member of the BCL9 family, grouped by HGNC with the Wnt enhanceosome complex.
HGNC lists no alternative symbols for BCL9. Its previous names are B cell CLL/lymphoma 9 and BCL9, transcription coactivator. UniProt names the protein B-cell CLL/lymphoma 9 protein. The current approved full name is BCL9 transcription coactivator.
NCBI Gene associates BCL9 with B-cell acute lymphoblastic leukaemia and suggests it may be a translocation target in B-cell malignancies with 1q21 abnormalities. The mouse ortholog is Bcl9. Check the datasheet of any product for its validated reactivity.
Other BCL-named genes and proteins, including transcription regulators and apoptosis-related family members, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O00512; product specifications from Assay Genie datasheets.